Mentor Capital 3Q 2026: Revenue $55.48K, EPS $0 — 10-Q Summary

Mentor Capital reported 3Q 2026 revenue of $55.48K, up 37.2% YoY, and EPS of $0, swinging to a profit. Growth was driven by higher royalty revenue and a $175,361 investment recovery, offsetting increased operating expenses and lower unrealized gains. Royalty revenue rose to $55,480 from $40,430 YoY, while operating expenses increased 4% to $209,167.

Original reporting
Published Nov 12, 2026, 7:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mentor Capital 3Q 2026: Revenue $55.48K, EPS $0 — 10-Q Summary — source image
Decision brief

The 30-second read

$MNTRBullishMed
01

Why it matters

The earnings beat and profit swing provide fresh data for traders to reassess valuation and short‑term price direction.

02

Market read

First‑time disclosure of improved earnings for a micro‑cap; may prompt short‑term price movement.

03

What to watch

The recovery of an impaired investment and unrealized securities losses could mask underlying cash‑flow weakness.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

Mentor Capital filed its Form 10‑Q for Q3 2026, revealing a 37.2% revenue increase and a swing to profit after a loss year‑over‑year.

Company-level read

Ticker impact

$MNTRBullishMedium confidence
Context

Mentor Capital reported Q3 2026 revenue of $55.48K and a swing to profit, marking its first 10‑Q disclosure of these figures.

Expected impact

likely upward pressure as the market prices in the profit swing and revenue growth

Evidence & confidence

The new earnings numbers are the first public disclosure and show a material improvement over the prior loss, which can trigger short‑term buying.

Market effects

Improved royalty revenue hints at modest strength in the oil‑and‑gas royalty sector.

Limited to U.S. micro‑cap investors; no broad regional effect.

Low global relevance; primarily a company‑specific update.

Counterpoint

The profit swing may be temporary if royalty revenue growth stalls or SG&A continues to rise.

Key entities

  • Mentor Capital, Inc.

    Micro‑cap investment firm reporting Q3 2026 results.

Related articles

$MNTRMedAI 8/10

Why is Munters stock surging today? By Investing.com

Munters shares rose 5.7% after the company’s Q2 2026 interim report. EPS was SEK 1.11 versus SEK 0.97 a year earlier, alongside “exceptionally strong” order intake. Munters said it is exploring divesting its FoodTech unit to focus on Data Center Technologies and AirTech, while citing US chiller ramp-up, delivery delays, and tariffs. Analysts: SEB cut target to SEK 180 (Hold); Nordea to SEK 238 (Buy).

$NEOVMedAI 8/10

NeoVolta Q1 Earnings Call Highlights

NeoVolta reported Q1 gross margin of 36.5%, expecting residential volume growth. Secured $116M agreement for 2027 deliveries, with $28.8M in cash. Net loss narrowed to $7.7M. Plans include commercial products in Q2 2027 and a fiscal year-end change to December 31, 2026. Collaborating with SK On for battery cells.

$ARWRHighAI 8/10

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Arrowhead Pharmaceuticals reported Q4 earnings, highlighting increased prescriptions for its drugs and potential future sales. The company expects $3B-$4B in annual U.S. sales for REDEMPLO if approved for SHTG. Operating expenses rose to $1.16B, but cash reserves increased to $1.2B. Arrowhead plans to track key metrics for an SHTG launch and has upcoming pipeline milestones in 2027.

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.